AU2018329937B2 - Proteins binding nkg2d, cd16 and nectin4 - Google Patents

Proteins binding nkg2d, cd16 and nectin4 Download PDF

Info

Publication number
AU2018329937B2
AU2018329937B2 AU2018329937A AU2018329937A AU2018329937B2 AU 2018329937 B2 AU2018329937 B2 AU 2018329937B2 AU 2018329937 A AU2018329937 A AU 2018329937A AU 2018329937 A AU2018329937 A AU 2018329937A AU 2018329937 B2 AU2018329937 B2 AU 2018329937B2
Authority
AU
Australia
Prior art keywords
ser
gly
seq
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018329937A
Other languages
English (en)
Other versions
AU2018329937A1 (en
Inventor
Gregory P. CHANG
Ann F. CHEUNG
Asya Grinberg
William Haney
Bradley M. LUNDE
Bianka Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapeutics Inc
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of AU2018329937A1 publication Critical patent/AU2018329937A1/en
Priority to AU2021201494A priority Critical patent/AU2021201494A1/en
Application granted granted Critical
Publication of AU2018329937B2 publication Critical patent/AU2018329937B2/en
Priority to AU2024278313A priority patent/AU2024278313A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018329937A 2017-09-07 2018-09-07 Proteins binding nkg2d, cd16 and nectin4 Active AU2018329937B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021201494A AU2021201494A1 (en) 2017-09-07 2021-03-09 Proteins binding NKG2D, CD16 and a tumor-associated antigen
AU2024278313A AU2024278313A1 (en) 2017-09-07 2024-12-11 Proteins binding NKG2D, CD16 and a tumor-associated antigen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762555110P 2017-09-07 2017-09-07
US62/555,110 2017-09-07
US201762566824P 2017-10-02 2017-10-02
US62/566,824 2017-10-02
PCT/US2018/050073 WO2019051308A1 (en) 2017-09-07 2018-09-07 NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2021201494A Division AU2021201494A1 (en) 2017-09-07 2021-03-09 Proteins binding NKG2D, CD16 and a tumor-associated antigen
AU2024278313A Division AU2024278313A1 (en) 2017-09-07 2024-12-11 Proteins binding NKG2D, CD16 and a tumor-associated antigen

Publications (2)

Publication Number Publication Date
AU2018329937A1 AU2018329937A1 (en) 2020-03-19
AU2018329937B2 true AU2018329937B2 (en) 2024-09-12

Family

ID=65634405

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018329937A Active AU2018329937B2 (en) 2017-09-07 2018-09-07 Proteins binding nkg2d, cd16 and nectin4
AU2021201494A Abandoned AU2021201494A1 (en) 2017-09-07 2021-03-09 Proteins binding NKG2D, CD16 and a tumor-associated antigen
AU2024278313A Pending AU2024278313A1 (en) 2017-09-07 2024-12-11 Proteins binding NKG2D, CD16 and a tumor-associated antigen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021201494A Abandoned AU2021201494A1 (en) 2017-09-07 2021-03-09 Proteins binding NKG2D, CD16 and a tumor-associated antigen
AU2024278313A Pending AU2024278313A1 (en) 2017-09-07 2024-12-11 Proteins binding NKG2D, CD16 and a tumor-associated antigen

Country Status (13)

Country Link
US (3) US20200277383A1 (enExample)
EP (2) EP3925976A1 (enExample)
JP (4) JP7431392B2 (enExample)
KR (3) KR20240167101A (enExample)
CN (3) CN119735693A (enExample)
AU (3) AU2018329937B2 (enExample)
BR (1) BR112020004489A2 (enExample)
CA (2) CA3074840A1 (enExample)
IL (2) IL273067A (enExample)
MX (2) MX420258B (enExample)
RU (1) RU2021110369A (enExample)
SG (2) SG10202102502VA (enExample)
WO (1) WO2019051308A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3511340T3 (da) 2016-08-10 2025-01-02 Univ Ajou Ind Academic Coop Found Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
TWI891611B (zh) 2018-10-23 2025-08-01 美商蜻蜓醫療公司 異二聚體fc融合蛋白
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN115427439A (zh) * 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
WO2021216916A1 (en) * 2020-04-22 2021-10-28 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
IL301163A (en) * 2020-09-17 2023-05-01 Agensys Inc Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
JP2024531382A (ja) * 2021-08-20 2024-08-29 タラック セラピューティクス，インク． ネクチン－４抗体およびコンジュゲート
KR20240087855A (ko) * 2021-09-29 2024-06-19 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 baff-r에 결합하는 단백질
KR20230060546A (ko) * 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
CN119907684A (zh) * 2022-07-25 2025-04-29 艾更斯司股份有限公司 用结合191p4d12蛋白的抗体药物偶联物(adc)与帕博利珠单抗组合治疗患有局部晚期或转移性尿道上皮癌的患者的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1423700A (zh) * 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
JP2003111595A (ja) * 2001-06-25 2003-04-15 Kyogo Ito 腫瘍抗原
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
US20070071759A1 (en) * 2005-06-29 2007-03-29 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2007067992A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
JP2012511305A (ja) * 2008-12-12 2012-05-24 オンコセラピー・サイエンス株式会社 癌の治療および診断の標的遺伝子としてのネクチン−４
CA2754531A1 (en) 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2011312417B2 (en) * 2010-09-29 2015-08-20 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN104271602B (zh) * 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
MX384142B (es) * 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
EP3083696B1 (en) * 2013-12-20 2018-02-14 F.Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
RU2016129724A (ru) * 2013-12-23 2018-01-30 Займворкс Инк. Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
ES2794557T3 (es) * 2015-09-09 2020-11-18 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad hacia nectina-4 y usos de los mismos
JP2020506971A (ja) * 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
FI3749346T3 (fi) * 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
EP4301774A4 (en) * 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2023168384A2 (en) * 2022-03-03 2023-09-07 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2

Also Published As

Publication number Publication date
SG10202102502VA (en) 2021-04-29
JP7431392B2 (ja) 2024-02-15
CN119735693A (zh) 2025-04-01
AU2018329937A1 (en) 2020-03-19
RU2021110369A (ru) 2021-06-01
CN111315782A (zh) 2020-06-19
KR20200044957A (ko) 2020-04-29
JP2025093943A (ja) 2025-06-24
US20230357409A1 (en) 2023-11-09
EP3679071A1 (en) 2020-07-15
JP2020533311A (ja) 2020-11-19
CA3074840A1 (en) 2019-03-14
IL273067A (en) 2020-04-30
JP2023166409A (ja) 2023-11-21
AU2024278313A1 (en) 2025-01-09
AU2021201494A1 (en) 2021-03-25
MX420258B (es) 2025-02-10
JP2021098733A (ja) 2021-07-01
CA3112984A1 (en) 2019-03-14
US20200277383A1 (en) 2020-09-03
KR20210030503A (ko) 2021-03-17
EP3679071A4 (en) 2021-06-09
EP3925976A1 (en) 2021-12-22
BR112020004489A2 (pt) 2020-09-08
KR20240167101A (ko) 2024-11-26
MX2021002970A (es) 2021-05-12
WO2019051308A1 (en) 2019-03-14
IL281323A (en) 2021-04-29
CN113004417A (zh) 2021-06-22
SG11202001930QA (en) 2020-04-29
MX2020002626A (es) 2020-10-07
US20210292420A1 (en) 2021-09-23
RU2020112333A (ru) 2021-10-08

Similar Documents

Publication Publication Date Title
US20230357409A1 (en) Proteins binding nkg2d, cd16 and nectin4
AU2020267226B2 (en) Multispecific binding proteins targeting nkg2d, cd16. and trop2
AU2018220734B2 (en) Proteins binding CD33, NKG2D and CD16
AU2018220736B2 (en) Proteins binding HER2, NKG2D and CD16
US20200277384A1 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
EP3882270A2 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
US20240018266A1 (en) Proteins binding cd123, nkg2d and cd16
US20190375838A1 (en) Proteins binding bcma, nkg2d and cd16
US20200157226A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CA3064743A1 (en) A protein binding nkg2d, cd16 and ror1 or ror2
AU2018309712A1 (en) Proteins binding NKG2D, CD16 and FLT3
US20210238290A1 (en) Proteins binding nkg2d, cd16 and p-cadherin
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
HK40062610A (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PROTEINS BINDING NKG2D, CD16 AND NECTIN4

FGA Letters patent sealed or granted (standard patent)